DNA Nanobots Closes Pre-seed Investment Round to Grow BioPharma Partner Program
Summary
"Most therapeutics fail in clinical trials," said CEO and co-founder Jeff Spitzner, Ph.D., "often because of insufficient payload into targets such as cancer cells, or off-target side effects resulting from delivery to the wrong tissues. DNA Nanobots provides design and development solutions customized around our Nanobots to target greater amounts of therapeutic molecules to only the intended cells which enables our partners to develop better treatments.Common therapeutic delivery strategies today employ technologies such as lipid nanoparticles (LNPs), antibody-drug conjugates (ADCs) or viral vectors. The company has several current partner projects making substantial steps towards clinical application, reporting excellent in vivo mouse study results and pharmacological profiles. "Now we invite potential investors to connect to discuss our anticipated next funding round at jspitzner@dnananobots.com," said Spitzner.DNA Nanobots is a platform biotechnology company pioneering the use of functionalized DNA nanoparticles to address challenges associated with targeted delivery of therapeutic payloads. We specialize in engineering custom cell-targeted solutions for our partners to deliver drugs, nucleic acids, antibodies, and immunotherapies.